Episode 37: Press Releases, Pre-Prints, Abstracts, and Papers – Reviewing the Peer-Review Process

Episode 37: Press Releases, Pre-Prints, Abstracts, and Papers – Reviewing the Peer-Review Process

Vincent Rajkumar, MD, Mayo Clinic, and Editor-in-Chief of Blood Cancer Journal, rejoins the show to answer some critically important questions related to medical publications and information reliability in the pandemic and post-pandemic world. As a consumer of medical news, which sources of information should you take seriously? Should you ignore press releases and pre-prints in favor of abstracts or papers? Should peer-reviewed literature be your only source of reliable information? Together, Chadi and Dr. Rajkumar put on their critical appraisal hats to rate various sources and determine when to adapt new guidelines or recommendations for patient care.

Related Resources

N/A

Subscribe to Healthcare Unfiltered

Other Episodes You May Enjoy...

Episode 223: From Lab to Statup: Dr. Simrit Parmar on Launching Cellenkos

Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous

Read More

Episode 222: Language Matters: A Patient Perspective

Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those

Read More

Episode 221: Major Progress in Adjuvant Renal Cell Carcinoma

Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease

Read More